Haisco Pharmaceutical Group Co., Ltd.

SZSE:002653 Stock Report

Market Cap: CN¥46.3b

Haisco Pharmaceutical Group Future Growth

Future criteria checks 4/6

Haisco Pharmaceutical Group is forecast to grow earnings and revenue by 33.7% and 19% per annum respectively. EPS is expected to grow by 34% per annum. Return on equity is forecast to be 16.1% in 3 years.

Key information

33.7%

Earnings growth rate

33.99%

EPS growth rate

Pharmaceuticals earnings growth14.9%
Revenue growth rate19.0%
Future return on equity16.15%
Analyst coverage

Low

Last updated08 May 2025

Recent future growth updates

Recent updates

An Intrinsic Calculation For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Suggests It's 30% Undervalued

Mar 24
An Intrinsic Calculation For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Suggests It's 30% Undervalued

Is Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Trading At A 38% Discount?

Dec 19
Is Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Trading At A 38% Discount?

Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares May Have Run Too Fast Too Soon

Nov 19
Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares May Have Run Too Fast Too Soon

Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

Aug 22
Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Jul 25
With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet

Jul 04
Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet

Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Jun 17
Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Earnings and Revenue Growth Forecasts

SZSE:002653 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20276,5009808341,2883
12/31/20265,3897436059443
12/31/20254,4465685218093
3/31/20253,861350-37401N/A
12/31/20243,7213951442N/A
9/30/20243,72247697513N/A
6/30/20243,672385143505N/A
3/31/20243,48435864447N/A
12/31/20233,35529559450N/A
9/30/20233,302375-171299N/A
6/30/20233,138282-447204N/A
3/31/20233,077280-441239N/A
1/1/20233,015277-60695N/A
9/30/20222,959173-57472N/A
6/30/20222,74495-61717N/A
3/31/20222,60784-715-39N/A
1/1/20222,773345-66736N/A
9/30/20212,866509-6951N/A
6/30/20213,154728-342290N/A
3/31/20213,469796-352289N/A
12/31/20203,330637-396206N/A
9/30/20203,326513-266515N/A
6/30/20203,520488-282499N/A
3/31/20203,68757221668N/A
12/31/20193,937494182764N/A
9/30/20194,32941316486N/A
6/30/20194,10542332365N/A
3/31/20193,788323107454N/A
12/31/20183,427333N/A473N/A
9/30/20182,624337N/A613N/A
6/30/20182,208247N/A571N/A
3/31/20182,061254N/A438N/A
12/31/20171,856238N/A392N/A
9/30/20171,806335N/A349N/A
6/30/20171,606341N/A313N/A
3/31/20171,535444N/A451N/A
12/31/20161,436443N/A409N/A
9/30/20161,342406N/A395N/A
6/30/20161,326395N/A474N/A
3/31/20161,147315N/A376N/A
12/31/20151,212372N/A443N/A
9/30/20151,179372N/A454N/A
6/30/20151,233434N/A455N/A
3/31/20151,226469N/A459N/A
1/1/20151,211451N/A503N/A
9/30/20141,110520N/A492N/A
6/30/20141,067524N/A522N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002653's forecast earnings growth (33.7% per year) is above the savings rate (2.7%).

Earnings vs Market: 002653's earnings (33.7% per year) are forecast to grow faster than the CN market (23.7% per year).

High Growth Earnings: 002653's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 002653's revenue (19% per year) is forecast to grow faster than the CN market (12.5% per year).

High Growth Revenue: 002653's revenue (19% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 002653's Return on Equity is forecast to be low in 3 years time (16.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/13 04:48
End of Day Share Price 2025/05/13 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Haisco Pharmaceutical Group Co., Ltd. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shanshan LiChina Merchants Securities Co. Ltd.
Sophia ZhangChina Stock Investment Research Co. Ltd. (GZ500..com)
Chao LiCitic Securities Co., Ltd.